What's Happening?
Eli Lilly has announced that its oral obesity therapy, Foundayo, has demonstrated safety in the ACHIEVE-4 trial, which is crucial for its approval in type 2 diabetes. The trial involved 2,700 patients and focused on the drug's safety concerning liver
and cardiovascular side effects. The results showed a 16% lower risk of major adverse cardiovascular events (MACE-4) and a 23% lower risk of MACE-3 compared to insulin glargine. Additionally, Foundayo-treated patients had a 57% reduced risk of all-cause death. The trial also confirmed no signs of drug-induced liver injury, addressing the FDA's primary safety concerns. Lilly plans to seek a national priority review for Foundayo in diabetes, potentially positioning it ahead of Novo Nordisk's Wegovy in the market.
Why It's Important?
The confirmation of Foundayo's safety is significant as it strengthens Eli Lilly's position in the competitive market for GLP-1 drugs, particularly against Novo Nordisk's Wegovy. The trial results not only support the drug's safety profile but also highlight its potential benefits in reducing cardiovascular risks and all-cause mortality. This could influence prescribing practices and patient preferences, especially for those with elevated cardiovascular risk. The approval for type 2 diabetes could expand Foundayo's market reach, impacting both the pharmaceutical industry and healthcare providers by offering a new treatment option with a favorable safety profile.
What's Next?
Eli Lilly is expected to file for a national priority review of Foundayo for type 2 diabetes, which could expedite its market entry. The company will likely continue to emphasize the drug's safety and efficacy in its marketing strategies, potentially influencing insurance coverage and healthcare provider recommendations. As the competition with Novo Nordisk intensifies, both companies may increase their efforts in marketing and establishing partnerships with healthcare providers to secure a larger market share.
